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ized trial. J Thorac Cardiovasc Surg. 2003;125:1363-71.Cost of thoracic endovascular aortic repair versus open repair and
implications for the US health care systemKaren L. Walker, BA, MHS, Paul Lipori, BA, MBA,W. Anthony Lee, MD, and Thomas Mark Beaver, MD,
Gainesville, FlaTABLE 1. Patient demographics and comorbidities in comparison
groups TEVAR versus open repair
TEVAR Open repair P value
Age 73.21 62.28 <.001
Female 42.86% (12/28) 34.48% (10/29) .516
Hypertension 78.57% (22/28) 89.66% (26/29) .251
Coronary artery
disease
32.14% (9/28) 27.59% (8/29) .707
COPD 42.86% (12/28) 20.69% (6/29) .072
CKD 0% (0/28) 17.24% (5/29) .052
TEVAR,Thoracic endovascular aortic repair;COPD, chronic obstructive pulmonary dis-
ease; CKD, chronic kidney disease.Following the 2005 FDA approval of the TAG endograft
(W. L. Gore & Associates, Inc, Flagstaff, Ariz), thoracic
endovascular aortic repair (TEVAR) utilization increased
dramatically.1 The clinical trial leading to approval of the
Gore-TAG thoracic stent graft demonstrated beneficial ef-
fects for early morbidity and mortality, with similar long-
term survival compared with open repair.2 However, there
remains a paucity of data comparing the costs of TEVAR
versus open repair. This study compared hospital costs and
physician relative value units (RVUs) between TEVAR
and open repair at a US academic institution.METHODS
Records from patients undergoing elective TEVAR and open repair of
distal arch and proximal descending thoracic aneurysms between January
2005 and December 2007 at a single academic institution were analyzed.
The hospital cost accounting system was used to compare mean costs in
the following categories: total hospitalization, total day of surgery, operat-
ing room, grafts, anesthesia, imaging, pharmacy, laboratory, and respira-
tory services. Costs were adjusted to 2007 dollars using the consumer
price index. Cost ratios are reported because hospital restrictions pro-
hibited reporting actual values. Age, gender, comorbidities, length of
stay (LOS), operating room time, and physician RVUs were examined.
Student t test was used for age, RVUs, and cost category variables.
Mann-Whitney test was used for median LOS. Pearson chi-square and
Fischer exact test were used for gender and comorbidity comparisons
(v17.0 SPSS, Chicago, Ill).DISCUSSION
Twenty-nine patients having open repair and 28 patients
having TEVAR were identified. Patients having TEVAR
were older, but comorbidities were similar between groups
(Table 1). Despite shorter surgical times for TEVAR (168
vs 465 minutes, P< .001), TEVAR operating room costs
were 2.03 times greater than open repair (P< .001). In-
creased operating room costs for TEVAR were secondary
to TEVAR graft costs, which were 22.2 times higher than
open repair. TEVAR grafts accounted for 74% of TEVAR
day of surgery costs, which were 1.32 times higher than
open repair (Figure 1). However, the total hospitalization
costs remained 1.55 times greater for open repair versus
TEVAR. Longer median LOS for open repair (20 days vs
6 days, P< .001) led to greater utilization of hospital ser-
vices. Anesthesia costs were 4.00 times greater for open
repair versus TEVAR (P< .001). Overall imaging costs
were 1.78 times greater for open repair versus TEVAR (P¼
.023). Pharmacy costs were 5.74 times greater for open re-
pair versus TEVAR (P ¼ .001). Laboratory costs were
4.94 times greater for open repair versus TEVAR (P <
.001). Respiratory services were 4.89 times greater for
open repair versus TEVAR (P ¼ .001). Despite shorterrdiovascular Surgery c Volume 139, Number 1 231
FIGURE 1. Relative cost analysis thoracic endovascular aortic repair (TEVAR) versus open repair. The cost ratio is depicted by having open repair as a con-
trol with cost equal to 1 with the relative cost of TEVARdetermined by taking the dollar amount for TEVAR and dividing by the dollar amount for open repair.
The overall total hospital costs are depicted in the first column with individual service lines depicted across the x-axis.
Brief Research Reportssurgical times, average RVUs were greater for TEVAR
versus open repair (97.74 vs 92.97, P ¼ 0.616).
In conclusion, TEVAR day of surgery costs are much
greater due to high endograft costs, although overall hospital
costs are greater for open repair. Assessment of in-hospital
costs reveals TEVAR to be a cost-effective treatment alter-
native in the short term. The cost-effectiveness of TEVAR
should improve if endograft costs decrease with dissemina-
tion of this technology. Importantly, this study does not
address the long-term costs of TEVAR. TEVAR patients
require lifelong monitoring similar to patients having endo-
vascular repair of abdominal aneurysms (EVAR). Analyses
of the long-term costs of EVAR are concerning and warrant
similar apprehensions for TEVAR. For example, one analy-232 The Journal of Thoracic and Cardiovascular Surgsis of the 5-year EVAR postprocedural costs revealed a 44%
incremental increase in the global cost compared with the
initial implantation cost.3 Further investigation of TEVAR
long-term costs is imperative for understanding current
and future impacts on the US health care system.References
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